Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04681482 · ClinicalTrials.gov registry record
Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 107,383
- Enrollment target
NCT04681482 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 107,383 participants.
The verdict
NCT04681482 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 107,383 participants
- Enrollment target
Study Summary
The overall objective of this analysis is to understand patient characteristics, the use of treatment, and clinical outcomes among obese (overweight) and severely obese patients with non-valvular atrial fibrillation (NVAF) who initiate therapy with OACs (oral anti-coagulants). The aim of this study is to compare all DOACs (direct oral anti-coagulants) to warfarin. However, the primary analysis will be conducted among apixaban vs warfarin patients only. If sample size permits, we will also conduct other DOAC vs warfarin and DOAC vs DOAC analysis.
Interventions
- DRUG Apixaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107,383 participants |
| Start Date | 2020-11-02 |
| Est. Completion | 2020-11-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04681482
The ClinicalTrials.gov registry entry for NCT04681482 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 107,383 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Apixaban is the first listed.
NCT04681482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04681482 about?
NCT04681482 is a clinical study titled "Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare". The overall objective of this analysis is to understand patient characteristics, the use of treatment, and clinical outcomes among obese (overweight) and severely obese patients with non-valvular atrial fibrillation (NVAF) who initiate therapy with OACs (oral anti-coagulants). The aim of this study ...
What is the current status of trial NCT04681482?
This trial is currently completed. The enrollment target is 107,383 participants. The study started on 2020-11-02. Estimated completion is 2020-11-03.
What interventions are being tested in trial NCT04681482?
The interventions under investigation include: Apixaban (DRUG).
Who is sponsoring clinical trial NCT04681482?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.